5-Amino-1MQ
C10H11N2+
159.21 g/mol · PubChem CID 950107
3 selected publications · 0 human intervention studies
Home / Research library / Other compounds
Other compounds: structures, studies & sources
Molecular records and selected literature for other research compounds. Names, salts and formulations are distinguished before comparing evidence or supplier packages.
150 catalog profiles · Source check 2026-10-09 · English research edition
29 profiles shown. A linked publication is not a recommendation for use. Human studies, preclinical experiments and reviews are labeled separately.
ACE-031
Molecular identity needs further verification
3 selected publications · 2 human intervention studies · 4 registered trials
AHK-Cu
Molecular identity needs further verification
1 selected publication · 0 human intervention studies
AICAR
C9H14N4O5
258.23 g/mol · PubChem CID 17513
4 selected publications · 3 human intervention studies · 4 registered trials
Small molecule · highest stage: Phase 3
Andarine (S4)
C19H18F3N3O6
441.4 g/mol · PubChem CID 9824562
5 selected publications · 0 human intervention studies
BAM15 Capsules
Molecular identity needs further verification
8 selected publications · 0 human intervention studies
Cardarine
C21H18F3NO3S2
453.5 g/mol · PubChem CID 9803963
8 selected publications · 0 human intervention studies · 3 registered trials
Small molecule · highest stage: Phase 2
Enclomiphene
C26H28ClNO
406.0 g/mol · PubChem CID 1548953
5 selected publications · 3 human intervention studies · 22 registered trials
Small molecule · highest stage: Phase 3
Follistatin 344
Molecular identity needs further verification
4 selected publications · 0 human intervention studies
HCG
Molecular identity needs further verification
4 selected publications · 1 human intervention study · 25 registered trials
US: active ingredient of an FDA-approved medicine · Drugs@FDA
L-Carnitine
C7H15NO3
161.20 g/mol · PubChem CID 10917
8 selected publications · 0 human intervention studies · 40 registered trials
Small molecule · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)
LGD-4033
C14H12F6N2O
338.25 g/mol · PubChem CID 44137686
8 selected publications · 1 human intervention study · 1 registered trial
Small molecule · highest stage: Phase 2
Methylene Blue Solution
C16H18ClN3S
319.9 g/mol · PubChem CID 6099
5 selected publications · 2 human intervention studies · 40 registered trials
US: active ingredient of an FDA-approved medicine · Drugs@FDA
Small molecule · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)
MGF
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
MK-677
C27H36N4O5S
528.7 g/mol · PubChem CID 178024
4 selected publications · 4 human intervention studies · 4 registered trials
Small molecule · highest stage: Phase 2
MK-777 (Acetamoren)
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
NAD+
C21H27N7O14P2
663.4 g/mol · PubChem CID 5892
1 selected publication · 1 human intervention study · 7 registered trials
Small molecule · highest stage: Phase 2
Orforglipron Capsules
C48H48F2N10O5
883.0 g/mol · PubChem CID 137319706
8 selected publications · 6 human intervention studies · 40 registered trials
Small molecule · highest stage: Phase 3
Ostarine
C19H14F3N3O3
389.33 g/mol · ChEMBL CHEMBL1738889
8 selected publications · 0 human intervention studies · 17 registered trials
Small molecule · highest stage: Phase 3
PEG MGF
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
RAD-140
C20H16ClN5O2
393.8 g/mol · PubChem CID 44200882
8 selected publications · 0 human intervention studies · 1 registered trial
Small molecule · highest stage: Phase 2
RAD-150 (TLB-150)
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
RU-58841
C17H18F3N3O3
369.34 g/mol · PubChem CID 132981
6 selected publications · 0 human intervention studies
S-23
C18H13ClF4N2O3
416.8 g/mol · PubChem CID 24892822
3 selected publications · 0 human intervention studies
SLU-PP-332
C18H14N2O2
290.3 g/mol · PubChem CID 5338394
3 selected publications · 0 human intervention studies
SR-9009 (Stenabolic)
C20H24ClN3O4S
437.9 g/mol · PubChem CID 57394020
8 selected publications · 0 human intervention studies
TB-500
Molecular identity needs further verification
1 selected publication · 0 human intervention studies · 1 registered trial
Tesofensine Capsules
C17H23Cl2NO
328.3 g/mol · PubChem CID 11370864
7 selected publications · 5 human intervention studies · 9 registered trials
Small molecule · highest stage: Phase 2
YK-11
C25H34O6
430.5 g/mol · PubChem CID 119058028
8 selected publications · 0 human intervention studies
How to read the library
Molecular values describe a specific source record. Salts, counterions, peptide sequences and modifications can change that identity. A 2D diagram is a reference depiction, not an analysis of a vendor batch. When a record is unresolved, we show the gap instead of assigning a similar molecule.
PubMed publication types help organize the selected bibliography; they do not grade study quality or prove a treatment effect. Reviews and encyclopedia articles provide context. The original methods, population, formulation, controls and limitations must be checked before interpreting an experiment.